Showing 1 - 8 results of 8 for search '"David Geffen School of Medicine at UCLA"', query time: 0.41s Refine Results
  1. 1
    Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease
    by Tashkin DP
    Published 2020-11-01
    “...Donald P Tashkin Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA...”
    Get full text
    Article
  2. 2
    Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
    by Tashkin DP, Ozol-Godfrey A, Sharma S, Sanjar S
    Published 2021-04-01
    “... and Critical Care Medicine, David Geffen School of Medicine at UCLA Health Sciences, Los Angeles, CA, USA; 2...”
    Get full text
    Article
  3. 3
    Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease
    by Tashkin DP, Wechsler ME
    Published 2018-01-01
    “...Donald P Tashkin,1 Michael E Wechsler2 1Department of Medicine, David Geffen School of Medicine...”
    Get full text
    Article
  4. 4
    Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
    by Tashkin DP, Gross NJ
    Published 2018-06-01
    “...Donald P Tashkin,1 Nicholas J Gross2 1Department of Medicine, David Geffen School of Medicine...”
    Get full text
    Article
  5. 5
    Exacerbation frequency and course of COPD
    by Halpin DMG, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP
    Published 2012-09-01
    “... School of Medicine at UCLA, Los Angeles, CA, USABackground: Exacerbations affect morbidity in chronic...”
    Get full text
    Article
  6. 6
    Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial
    “... Shekar5, Sibabrata Banerjee5, Heribert Staudinger51David Geffen School of Medicine at UCLA, Los Angeles...”
    Get full text
    Article
  7. 7
    Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD
    “... of Kentucky, Lexington, KY, 2David Geffen School of Medicine at UCLA, Los Angeles, CA, 3Clinical Research...”
    Get full text
    Article
  8. 8
    Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials
    “... Shekar5, Davis Gates5, Heribert Staudinger51David Geffen School of Medicine at UCLA, Los Angeles, CA, 2...”
    Get full text
    Article
Search Tools: Get RSS Feed — Email this Search